Does Omega-3 Cardiovascular Randomized Trial work?

The current Migaku evidence database contains 2 reusable source documents for Omega-3 Cardiovascular Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - Neutral findings likely reflect moderate-dose combined EPA + DHA use, limited subgroup reporting on metabolic comorbidities (e.g., diabetes, hypertriglyceridemia) or concomitant therapies (e.g., statins), and high background guideline-directed medical therapy reducing residual risk. [Shayan SK (2026); evidence level 1] - Although omega-3 fatty acids exert anti-inflammatory, antithrombotic, and lipid-modulating effects, this analysis indicates no broad benefit in reducing MACE or AF risk with combined moderate-dose EPA + DHA in heterogeneous post-event populations. [Shayan SK (2026); evidence level 1] - Recent evidence highlights more MACE reductions with high-dose purified EPA monotherapy in high-metabolic-risk subgroups, balanced against dose-dependent AF increases at high doses (> 1.5 g/day). [Shayan SK (2026); evidence level 1] - Cardiovascular diseases (CVD) remain to impose a main global burden of morbidity and mortality despite advances in anticipation and treatment. [Shayan SK (2026); evidence level 1] - Most prior omega-3 outcome trials enrolled patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, but none specifically targeted patients receiving dialysis. [Mazón-Ruiz Jaime (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.